ctDNA Tracks Relapse Risk in Breast Cancer - Summary - MDSpire

ctDNA Tracks Relapse Risk in Breast Cancer

Personalized liquid biopsy testing identified molecular residual disease months before clinical recurrence

  • June 9, 2026

  • 2 min

Share

Objective:

To evaluate the effectiveness of ctDNA monitoring in predicting relapse and survival outcomes in early breast cancer patients compared to standard treatment response measures.

Key Findings:
  • Persistence of ctDNA after neoadjuvant therapy was strongly associated with recurrence and death.
  • Patients with cleared ctDNA during treatment had significantly better outcomes.
  • ctDNA dynamics were more prognostic than pathologic complete response.
  • ctDNA detection often preceded clinical relapse by a median of 13.8 months.
Interpretation:

Limitations:
Conclusion:

Original Source(s)

ctDNA Tracks Relapse Risk in Breast Cancer

  • June 9, 2026

Related Content

India, and its Diagnostic Influence

Kunal Sharma explains how digital pathology, genomics, and integrated diagnostics are reshaping cancer care across India and beyond

A case report of thyroid-like low-grade nasopharyngeal papillary adenocarcinoma with literature review

ASCO 2026: FDA-Cleared AI Put to the Test

Multimodal AI platform goes head-to-head with a standard breast cancer assay using routine pathology image

  • June 3, 2026

  • 3 min